Cortical Blindness:Etiology, Diagnosis, & Prognosis
Ann Neurol 21:149-158, Aldrich,M.S.,et al, 1987
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Visual Impairment in Children with Epilepsy Treated with Vigabatrin
Ann Neurol 48:60-64, Gross-Tsur,V. et al, 2000
Infantile Neuroaxonal Dystrophy,Clinical Spectrum and Diagnostic Criteria
Neurol 52:1472-1478, Nardocci,N.,et al, 1999
Vigabatrin-Associated Retinal Cone System Dysfunction, Electroretinogram & Ophthalmol Findings
Neurol 50:614-618, Krauss,G.L.,et al, 1998
A Man Who Lost Weight and His Sight
Lancet 351:1174-1175, Moschos,M.&Droutsas,D., 1998
Vision and Hearing During Deferoxamine Therapy
J Pediatr 117:326-330, Cohen,A.,et al, 1990
Neurosarcoidosis:Signs, Course and Treatment in 35 Confirmed Cases
Medicine 69:261-276, Chapelon,C.,et al, 1990
Visual Evoked Potentials in the Detection of Subclinical Optic Toxic Effects Secondary to Ethambutol
Arch Neurol 40:645-648, Yiannikas,C.,et al, 1983
New Diagnostic Criteria for Multiple Sclerosis:Guidelines for Research Protocols
Neurol 13:227-231, Poser,C.M.,et al, 1983
Carotid Occlusive Disease, Effect of Bright Light on Visual Evoked Response
Arch Neurol 39:687-689, Donnan,G.A.,et al, 1982
Central Achromatopsia:Behavioral, Anatomic, & Physiologic Aspects
Neurol 30:1064-1071, Damasio,A.,et al, 1980